You are here: Industry Insights > Roche

News List

Roche’s Tecentriq improves disease-free survival in early lung cancer pharmatimes
March 22, 2021
Roche’s PD-L1 inhibitor Tecentriq significantly improved disease-free survival (DFS) in patients with resectable, early stage non-small cell lung cancer (NSCLC), according to newly published Phase III data.
FDA Warns of Potential False Results with Roche Molecular Systems for COVID, Flu Test americanpharmaceuticalreview
March 22, 2021
The U.S. Food and Drug Administration (FDA) is alerting clinical laboratory staff, point-of-care (POC) facility staff, and health care providers that false positive results can occur with the Roche Molecular Systems, Inc. (Roche) cobas SARS-CoV-2 & ...
Roche Receives FDA approval for VENTANA ALK CDx Assay with LORBRENA americanpharmaceuticalreview
March 12, 2021
Roche announced US Food and Drug Administration (FDA) approval of the VENTANA ALK (D5F3) CDx Assay as a companion diagnostic to identify ALK-positive non-small cell lung cancer (NSCLC) patients eligible for treatment with Pfizer's drug LORBRENA® ...
Roche to withdraw US indication for Tecentriq in bladder cancer pharmaceutical-technolog
March 10, 2021
Roche is set to voluntarily withdraw the US indication for Tecentriq (atezolizumab) in prior platinum treated metastatic urothelial carcinoma (mUC, bladder cancer) following its consultation with the US Food and Drug Administration (FDA).
Sales of injectable anti-HIV therapeutics will reach $2 billion in 2029: GlobalData expresspharma
March 01, 2021
Cabotegravir-based therapies are projected to generate 79 per cent of the sales of injectable therapeutics in the HIV market in 2029.
Roche’s vision loss therapy faricimab extends time between treatments by up to four months pharmatimes
February 20, 2021
Roche’s investigational bispecific antibody faricimab has been found to extend the time between treatments by up to four months in patients with diabetic macular edema (DME) and neovascular age-related macular degeneration (nAMD).
Roche announces the upcoming launch of the SARS-CoV-2 Rapid Antigen Test Nasal allowing for patient self-collection worldpharmanews
February 07, 2021
Roche announced it has obtained the CE mark for its new SARS-CoV-2 Rapid Antigen Test Nasal. The test will be available in countries accepting the CE mark by mid-February 2021.
Financial Report. Roche contractpharma
February 07, 2021
Newly launched medicines Tecentriq, Hemlibra, Ocrevus, Perjeta and Kadcyla offset the impact of competition from biosimilars for established medicines.
Affimed, Roche Explore AFM24, Tecentriq Combo contractpharma
February 04, 2021
Affimed N.V., a clinical-stage immuno-oncology company, entered a clinical research collaboration with Roche to explore the combination of Affimed’s innate cell engager (ICE) AFM24 with Roche’s PD-L1 checkpoint inhibitor atezolizumab (Tecentriq).
Roche’s faricimab hits primary endpoint in wet AMD studies pharmatimes
January 27, 2021
Roche’s investigational bispecific antibody faricimab has hit the primary endpoint in two Phase III studies in people living with neovascular or wet age-related macular degeneration (nAMD).

Previous page 1 2 3 4 5 6 7 8 9 10 ... 45 46 Next page